13096-96-3 Usage
General Description
4-Chloro (1H)indazole is a chemical compound that belongs to the indazole class of heterocyclic aromatic organic compounds. It is characterized by a chloro substitution at the 4-position of the indazole ring. 4-CHLORO (1H)INDAZOLE is commonly used as a building block in the synthesis of pharmaceutical drugs, agrochemicals, and other organic compounds. It has been studied for its potential pharmacological properties, particularly as an antitumor and anti-inflammatory agent. Additionally, 4-chloro (1H)indazole is used in research and development as a starting material for the synthesis of novel compounds with potential therapeutic applications.
Check Digit Verification of cas no
The CAS Registry Mumber 13096-96-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,3,0,9 and 6 respectively; the second part has 2 digits, 9 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 13096-96:
(7*1)+(6*3)+(5*0)+(4*9)+(3*6)+(2*9)+(1*6)=103
103 % 10 = 3
So 13096-96-3 is a valid CAS Registry Number.
InChI:InChI=1/C7H5ClN2/c8-6-2-1-3-7-5(6)4-9-10-7/h1-4H,(H,9,10)
13096-96-3Relevant articles and documents
An improved preparation of 4-chloro-1H-indazole
Meng, Ge,Yang, Tao,Liu, Yang
, p. 354 - 359 (2011)
-
Enzymic synthesis and biochemical activity of various indazole adenine dinucleotides
Tono-Oka,Tone,Marquez,et al.
, p. 309 - 315 (1985)
-
CHEMICAL COMPOUNDS
-
Page/Page column 50, (2018/03/06)
The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
ALKYNYL ALCOHOLS AND METHODS OF USE
-
Page/Page column 166, (2015/03/13)
The invention relates to compounds of Formula (0): wherein Q, A1-A8, R4 and R5 and each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over- activation of NF-kB signaling is observed.
